Stifel Nicolaus analyst James Orsborne has reiterated their bullish stance on OXBDF stock, giving a Buy rating on October 6.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
James Orsborne has given his Buy rating due to a combination of factors that highlight Oxford BioMedica’s strong market positioning and growth potential. The company is strategically positioned to capture both current and future growth opportunities in the cell and gene therapy sector, supported by scalable capacity and a robust portfolio of later-stage programs. The recent equity raise and acquisition of a US commercial site have significantly bolstered Oxford BioMedica’s capabilities in the US market, enhancing its ability to secure new business.
Furthermore, Oxford BioMedica’s financial outlook is compelling, with attractive valuation metrics and a clear path to profitability as indicated by management’s guidance for midterm growth and margin expansion. The company’s strategic shift to focus solely on contract development and manufacturing operations has sharpened its investment case, with a diverse client base and a significant portion of its pipeline in advanced clinical stages. This positions Oxford BioMedica as a standout investment in the UK-listed life sciences sector, with its competitive advantages yet to be fully recognized by the market.
According to TipRanks, Orsborne is ranked #9627 out of 10041 analysts.
In another report released on October 6, RBC Capital also reiterated a Buy rating on the stock with a p970.00 price target.